Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models

YUKI NIWA, MAKOTO ASANO, TAKAYUKI NAKAGAWA, DAMIEN FRANCE, TARO SEMBA and YASUHIRO FUNAHASHI
Anticancer Research December 2020, 40 (12) 6699-6712; DOI: https://doi.org/10.21873/anticanres.14693
YUKI NIWA
1Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MAKOTO ASANO
1Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKAYUKI NAKAGAWA
1Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DAMIEN FRANCE
2Oncodesign, Dijon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TARO SEMBA
1Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YASUHIRO FUNAHASHI
1Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: y-funahashi@hhc.eisai.co.jp
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 40 no. 12 6699-6712
DOI 
https://doi.org/10.21873/anticanres.14693
PubMed 
33288563

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received October 30, 2020
  • Revision received November 15, 2020
  • Accepted November 16, 2020
  • Published online December 7, 2020.

Copyright & Usage 
Copyright © 2020 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Author Information

  1. YUKI NIWA1,
  2. MAKOTO ASANO1,
  3. TAKAYUKI NAKAGAWA1,
  4. DAMIEN FRANCE2,
  5. TARO SEMBA1 and
  6. YASUHIRO FUNAHASHI⇑1
  1. 1Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan;
  2. 2Oncodesign, Dijon, France
  1. Correspondence to: Yasuhiro Funahashi, Tsukuba Research Laboratories, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki, 300-2635, Japan. Tel: +81 298475615, Fax: +81 298477614, e-mail: y-funahashi{at}hhc.eisai.co.jp
View Full Text
PreviousNext
Back to top

In this issue

Anticancer Research: 40 (12)
Anticancer Research
Vol. 40, Issue 12
December 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 8 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models
YUKI NIWA, MAKOTO ASANO, TAKAYUKI NAKAGAWA, DAMIEN FRANCE, TARO SEMBA, YASUHIRO FUNAHASHI
Anticancer Research Dec 2020, 40 (12) 6699-6712; DOI: 10.21873/anticanres.14693

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models
YUKI NIWA, MAKOTO ASANO, TAKAYUKI NAKAGAWA, DAMIEN FRANCE, TARO SEMBA, YASUHIRO FUNAHASHI
Anticancer Research Dec 2020, 40 (12) 6699-6712; DOI: 10.21873/anticanres.14693
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The Mechanism of the Synergistic Anticancer Effect of CDDP and EPA in the TE1 Cell Line
  • Ephrin Receptor A4 Expression Enhances Migration, Invasion and Neurotropism in Pancreatic Ductal Adenocarcinoma Cells
  • Oral-recombinant Methioninase Converts an Osteosarcoma from Docetaxel-resistant to -Sensitive in a Clinically-relevant Patient-derived Orthotopic-xenograft (PDOX) Mouse Model
Show more Experimental Studies

Similar Articles

Keywords

  • CDK4/6 inhibitor
  • eribulin mesylate
  • luminal-type breast cancer
  • patient-derived xenograft model
  • reversal of epithelial-mesenchymal transition
  • preclinical trial
Anticancer Research

© 2021 Anticancer Research

Powered by HighWire